Greenwich LifeSciences (GLSI) Common Equity (2019 - 2025)

Greenwich LifeSciences' Common Equity history runs 7 years deep, the most recent figure standing at $353217.0 for Q4 2025.

• Quarterly Common Equity fell 61.13% year-over-year to $353217.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $353217.0 (down 61.13% YoY) and the FY2025 annual result came in at $353217.0, down 61.13% from the prior year.
• Common Equity was $353217.0 for Q4 2025 at Greenwich LifeSciences, down from $2.2 million in the prior quarter.
• Across five years, Common Equity topped out at $29.7 million in Q1 2021 and bottomed at $353217.0 in Q4 2025.
• A 5-year average of $12.0 million and a median of $9.8 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 2193.22% — and 2024, when it sank 86.44%.
• Greenwich LifeSciences' Common Equity stood at $26.8 million in 2021, then sank by 50.75% to $13.2 million in 2022, then plunged by 49.29% to $6.7 million in 2023, then slumped by 86.44% to $908626.0 in 2024, then sank by 61.13% to $353217.0 in 2025.
• Business Quant data shows GLSI's Common Equity at $353217.0 in Q4 2025, $2.2 million in Q3 2025, and $1.4 million in Q2 2025.